Paying for Mental Health Care

Why a Spravato Appointment Takes Two Hours

Save

Spravato appointments run about two hours because federal safety rules require on-site observation after every dose, watching for sedation, dissociation, and blood-pressure changes. This walkthrough covers what each visit looks like start to finish, why the driving restriction lasts until the next day, and how to plan the schedule.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Why do you stay two hours after the spray?

Supervised observation is the reason the visit is long. Esketamine's most predictable short-term effects -- sleepiness, a temporarily dream-like or detached feeling, and a short-lived rise in blood pressure -- appear soon after a dose and, for most people, settle during the visit itself. The federal risk-management program (a REMS) under which Spravato was approved requires that every dose be taken at the treatment site with monitoring until staff clear you to leave, an observation window of about two hours described in ICER's evidence review of esketamine 1. Cost-effectiveness analyses price the treatment the same way -- drug plus supervised administration and observation time, not a prescription you fill and take home 2. The two hours are the safety architecture, not clinic inefficiency.

What actually happens during the visit?

Check-in starts with a brief pre-dose assessment: how you've been since the last visit, plus a blood-pressure reading. You then administer the nasal spray yourself while a clinician supervises. The long middle of the appointment is the quiet part -- typically a reclining chair in a low-stimulation room, with staff checking in at intervals and repeating blood-pressure measurements as the monitoring protocol requires 1. Reading or working through that stretch is usually unrealistic; many people bring headphones or an eye mask and treat it as enforced rest. Before you leave, a discharge check confirms the acute effects have faded enough to go home with your ride. Clinic routines vary in the details, so the intake visit is where yours gets explained.

Why can't you drive until the next day?

The ride-home rule is part of the same safety program: after each dose, patients are not to drive or operate machinery until the following day, after a restful sleep 1. The logic is that sedation and dissociation can outlast the visit's obvious effects, so the restriction extends past the point where you feel normal. Practically, that means every appointment needs a plan -- a friend or family member, a rideshare, or transit -- and many clinics confirm the plan at check-in before dosing. Treating the ride as part of the appointment, rather than an afterthought, is the single biggest scheduling adjustment new patients report. What the driving restriction means in practice covers the common workarounds.

Why is Spravato only given at certified centers?

Certification is a condition of the safety program: Spravato is dispensed and used on-site at enrolled clinics rather than filled at a pharmacy, which is why certified centers are the only place to get it. Claims-based research on U.S. access describes treatment concentrated at these certified sites and the real visit burden that structure creates 3. Scheduling follows a rhythm your prescriber sets: visits are more frequent in the first weeks and space out over time, so the early phase means blocking several two-hour windows plus travel. For context on the tradeoff, treatment-resistant depression itself carries measured costs in lost work and disability days 4 -- which is why many people decide the visit burden is worth planning around rather than a reason to rule the option out.

Planning the logistics with your care team

Logistics questions are legitimate clinical questions here, and the intake conversation is the place to ask them: which days the clinic runs observation slots, whether early-morning or late-afternoon windows exist around work, how the visit frequency is expected to change over time, and what each visit will cost under your plan -- Spravato's per-session cost picture and whether insurance covers it are their own topics. If you're still weighing esketamine against other options, a psychiatrist can map where it fits your treatment history among the wider set of depression treatments. A care team that knows your schedule constraints up front can usually build around them.

Common questions

No. The federal safety program requires that you not drive until the next day, after a restful sleep, and clinics expect a ride plan -- a friend, family member, rideshare, or transit -- before dosing.

Most acute effects settle within the observation window -- that is what the discharge check confirms -- but some grogginess can linger, which is why the driving restriction extends to the next day rather than ending at the clinic door.

Visits are typically more frequent during the first weeks of treatment and space out over time on a schedule your prescriber sets. Each visit keeps the same roughly two-hour shape regardless of where you are in the course.

Usually not realistically. The middle stretch of the visit is intentionally low-stimulation, and the temporary sedation and dissociative effects make focused work difficult. Most patients plan it as downtime with music or rest.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

If things feel heavy, a person is available anytime — call or text 988.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When something needs attention between appointments

  • —Worsening depression or thoughts of suicide between scheduled visits
  • —Severe or persistent symptoms after leaving the clinic, rather than effects that fade the same day
  • —A crisis that can't wait for the next scheduled appointment

This article describes the general structure federal safety rules require; your clinic's specific protocol and your prescriber's plan govern your treatment. This is general information, not medical advice. If you are in crisis, call or text 988 (Suicide & Crisis Lifeline) -- free, confidential, available 24/7.

References

  1. 1.Agboola F et al. (2020). The Effectiveness and Value of Esketamine for the Management of Treatment-Resistant Depression. Journal of Managed Care & Specialty Pharmacy (JMCP). doi:10.18553/jmcp.2020.26.1.16 ✓esketamine-cost-effectivenessesketamine-value-assessmenticer-reporttreatment-resistant-depression-cost
  2. 2.Ross EL & Soeteman DI (2020). Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States. Psychiatric Services. doi:10.1176/appi.ps.201900625 ✓esketamine-cost-effectivenessspravato-accesstreatment-resistant-depression-cost
  3. 3.Zhdanava M et al. (2023). Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States. Journal of Medical Economics. doi:10.1080/13696998.2023.2208993 ✓esketamine-coveragespravato-accessclaims-based-utilizationinterventional-access
  4. 4.Jha MK et al. (2025). Mental Health-Related Disability Days and Costs Among Patients with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray and Conventional Therapies in the USA. Drugs - Real World Outcomes. doi:10.1007/s40801-024-00478-3 ✓esketamine-coveragedisability-and-costtreatment-resistant-depression-costinterventional-access

4 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library